睿知中国医院研究地图
候选清单

上海上海中医药大学

上海中医药大学附属龙华医院

Longhua Hospital

在本站收录的 61 种疾病中,这家医院列在其中 16 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

上海中医药大学附属龙华医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma7 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma11 篇牵头论文
  3. 胃癌Stomach cancer13 篇牵头论文
  4. 肺癌Lung cancer44 篇牵头论文
  5. 乳腺癌Breast cancer36 篇牵头论文
  6. 脊索瘤Chordoma1 篇牵头论文
  7. 骨肉瘤Osteosarcoma4 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  9. 血友病 AHaemophilia A1 篇牵头论文
  10. 冠心病Coronary heart disease5 篇牵头论文牵头 1 项开放试验
  11. 脊柱侧弯Scoliosis2 篇牵头论文
  12. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  13. IgA 肾病IgA nephropathy1 篇牵头论文
  14. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  15. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
  16. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:鼻咽癌、胰腺癌、胶质瘤、肝母细胞瘤、视网膜母细胞瘤、胃肠道间质瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、先天性心脏病、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.2%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 1120232024: 1120242025: 222025

上海有 18 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因免疫治疗

这些论文过半是实验室或动物研究。

牵头的论文7
  1. High antigen-presenting CAF levels correlate with reduced glycosaminoglycan biosynthesis-heparan sulfate/heparin metabolism in immune cells and poor prognosis in esophageal squamous cell carcinoma: Insights from bulk and single-cell transcr2025International journal of biological macromolecules
  2. Reversal of amino acid metabolism patterns between circulating blood and tumors as a new biomarker for the Zhengxu Xieshi syndrome in patients with esophageal squamous cell carcinoma.2025Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan免费全文
  3. Unveiling the methionine cycle: a key metabolic signature and NR4A2 as a methionine-responsive oncogene in esophageal squamous cell carcinoma.2024Cell death and differentiation免费全文
  4. Evodiamine inhibits ESCC by inducing M-phase cell-cycle arrest via CUL4A/p53/p21 axis and activating noxa-dependent intrinsic and DR4-dependent extrinsic apoptosis.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  5. New Metabolic Alterations and A Predictive Marker Pipecolic Acid in Sera for Esophageal Squamous Cell Carcinoma.2022Genomics, proteomics & bioinformatics免费全文
  6. Daurisoline Inhibits ESCC by Inducing G1 Cell Cycle Arrest and Activating ER Stress to Trigger Noxa-Dependent Intrinsic and CHOP-DR5-Dependent Extrinsic Apoptosis via p-eIF2α-ATF4 Axis.2022Oxidative medicine and cellular longevity免费全文
  7. A multi-omics study delineates new molecular features and therapeutic targets for esophageal squamous cell carcinoma.2021Clinical and translational medicine免费全文
PubMed 以外找到的论文(未计入)1
  1. Long non-coding RNA NCK1-AS1 functions as a ceRNA to regulate cell viability and invasion in esophageal squamous cell carcinoma via microRNA-133b/ENPEP axis2022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.07%。

牵头论文
11
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 2220242025: 442025

上海有 16 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题手术与肝移植局部治疗(消融、TACE、HAIC)免疫与靶向药物
论文中的科室肿瘤内科消化/肝病科影像/核医学科临床试验/研究机构

这些论文过半是实验室或动物研究。

牵头的论文11
  1. Decoding the epigenetic-immune nexus in hepatocellular carcinoma: a Mendelian randomization study reveals BTN3A2, S100A12 and TRIM27 as white blood cell regulators.2025BMC cancer免费全文
  2. Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation.2025Cancer medicine免费全文
  3. ERG mediates the differentiation of hepatic progenitor cells towards immunosuppressive PDGFRα+ cancer-associated fibroblasts during hepatocarcinogenesis.2025Cell death & disease免费全文
  4. FABP5+ lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity.2025Journal of hepatology
  5. SCFFBXW5-mediated degradation of AQP3 suppresses autophagic cell death through the PDPK1-AKT-MTOR axis in hepatocellular carcinoma cells.2024Autophagy免费全文
  6. Therapeutic potential of traditional Chinese medicine in the prevention and treatment of digestive inflammatory cancer transformation: Portulaca oleracea L. as a promising drug.2024Journal of ethnopharmacology
  7. Circ_0004913 Inhibits Cell Growth, Metastasis, and Glycolysis by Absorbing miR-184 to Regulate HAMP in Hepatocellular Carcinoma.2023Cancer biotherapy & radiopharmaceuticals
  8. Exploring the mechanism of Jianpi Huatan recipe in protecting hepatocellular carcinoma based on network pharmacology.2023Journal of ethnopharmacology
  9. Dual-Energy Computed Tomography Imaging in Early-Stage Hepatocellular Carcinoma: A Preliminary Study.2022Contrast media & molecular imaging免费全文
  10. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  11. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma状态不明NCT02969096牵头方(推断)II期2016-10 启动
  2. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)已完成NCT04000737研究中心II期2020-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.1%。

牵头论文
13
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 1120232024: 5520242025: 222025

上海有 17 家医院列在胃癌下全国有 211 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题免疫与靶向药物影像与人工智能腹膜转移与晚期
论文中的科室肿瘤内科消化/肝病科病理/检验科
牵头的论文13
  1. Morin inhibits ubiquitination degradation of BCL-2 associated agonist of cell death and synergizes with BCL-2 inhibitor in gastric cancer cells.2025Journal of integrative medicine
  2. Potential of traditional Chinese medicine in managing and preventing Helicobacter pylori infection in Chinese military.2025World journal of gastroenterology免费全文
  3. Chinese Medicine Prolongs Overall Survival of Chinese Patients with Advanced Gastric Cancer: Treatment Pattern and Survival Analysis of a 20-Year Real-World Study.2024Chinese journal of integrative medicine
  4. NRF2 inhibits RSL3 induced ferroptosis in gastric cancer through regulation of AKR1B1.2024Experimental cell research
  5. Chronic atrophic gastritis and risk of incident upper gastrointestinal cancers: a systematic review and meta-analysis.2024Journal of translational medicine免费全文
  6. ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer.2024Pharmacological research
  7. Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors.2024World journal of gastroenterology免费全文
  8. Efficacy of luteolin on the human gastric cancer cell line MKN45 and underlying mechanism.2023Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan免费全文
  9. Acacetin inhibits invasion, migration and TGF-β1-induced EMT of gastric cancer cells through the PI3K/Akt/Snail pathway.2022BMC complementary medicine and therapies免费全文
  10. Effects of traditional Chinese medicine collaborative model (TCMCM) combined with adjuvant chemotherapy on IIIb and IIIc gastric cancer: a protocol for a randomized controlled trial.2022Trials免费全文
  11. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.2021DNA and cell biology
  12. Drug metabolism-related eight-gene signature can predict the prognosis of gastric adenocarcinoma.2021Journal of clinical laboratory analysis免费全文
  13. Predicting gastric cancer outcome from resected lymph node histopathology images using deep learning.2021Nature communications免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer已完成NCT03607656牵头方(推断)II/III期2018-06 启动
  2. Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score状态不明NCT02781285牵头方(推断)2014-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 44 篇,占 0.2%。

牵头论文
44
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 6620222023: 9920232024: 131320242025: 662025

上海有 22 家医院列在肺癌下全国有 251 家医院列在肺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的肺癌开放试验。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科放疗科

这些论文过半是实验室或动物研究。

牵头的论文44
  1. Formosanin C inhibits infiltration of MDSCs by activating the STING pathway in non-small cell lung cancer.2026International immunopharmacology
  2. Amentoflavone from Ginkgo biloba inhibits EMT-driven lung cancer metastasis by targeting TGFBR2: Integrative network pharmacology, machine learning, and experimental validation.2026Journal of ethnopharmacology
  3. Opportunistic muscle density assay during CT lung cancer screening for low muscle quality evaluation in older adults: a multicenter study.2025Aging clinical and experimental research免费全文
  4. Treatment of Tislelizumab-Induced Toxic Epidermal Necrolysis and Agranulocytosis: A Case Report and Literature Review.2025Current drug safety免费全文
  5. Local anesthetic ropivacaine inhibits non-small cell lung cancer progression by modulating the hsa_circ_0001320/miR-518a-5p axis.2025Hereditas免费全文
  6. YinxingGujin decoction suppresses lung adenocarcinoma metastasis by modulating the TGF-β/STAT3/PD-L1 Axis: Network pharmacology and experimental validation.2025Journal of ethnopharmacology
  7. Jiawei Yanghe Decoction augments intratumoral CD8+ TIL infiltration and enhances radiotherapy efficacy in non-small cell lung cancer through CXCR3 ligand-mediated chemotaxis.2025Journal of ethnopharmacology
  8. Role of Traditional Chinese Medicine in Lung Cancer Management: A Review.2025The American journal of Chinese medicine
  9. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature.2024Diagnostic pathology免费全文
  10. SENP2-NDR2-p21 axis modulates lung cancer cell growth.2024European journal of pharmacology
  11. Oral Decoctions Based on Qi-Yin Syndrome Differentiation After Adjuvant Chemotherapy in Resected Stage ΙΙΙA Non-Small Cell Lung Cancer: A Randomized Controlled Trial.2024Integrative cancer therapiesRCT免费全文
  12. Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma.2024International immunopharmacology
  13. A commentary on 'Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study'.2024International journal of surgery (London, England)免费全文
  14. Synergetic approaches of fucoidan and trabectedin complex coated PLGA nanoparticles effectively suppresses proliferation and induce apoptosis for the treatment on non-small cell lung cancer.2024Journal of biomaterials science. Polymer edition
  15. Integrating single-cell and multi-omic approaches reveals Euphorbiae Humifusae Herba-dependent mitochondrial dysfunction in non-small-cell lung cancer.2024Journal of cellular and molecular medicine免费全文
  16. Cycloastragenol induces apoptosis and protective autophagy through AMPK/ULK1/mTOR axis in human non-small cell lung cancer cell lines.2024Journal of integrative medicine
  17. Comment on "Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis".2024Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  18. Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC.2024Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  19. A pilot study of precision treatment for patients with lung cancer pain by Longteng Tongluo recipe using serum genomics.2024Journal of traditional Chinese medicine = Chung i tsa chih ying wen panRCT免费全文
  20. Significance of NKX2-1 as a biomarker for clinical prognosis, immune infiltration, and drug therapy in lung squamous cell carcinoma.2024PeerJ免费全文
  21. Study on the difference and regularity of tongue images in 309 patients with different pathological stages of non-small cell lung cancer.2024Technology and health care : official journal of the European Society for Engineering and Medicine免费全文
  22. Acute myocardial infarction due to coronary embolism caused by a metastatic mass from lung cancer.2023BMC cardiovascular disorders免费全文
  23. Exosomal lncRNA HOTAIR promotes osteoclast differentiation by targeting TGF-β/PTHrP/RANKL pathway.2023Basic & clinical pharmacology & toxicology
  24. Fructose utilization enhanced by GLUT5 promotes lung cancer cell migration via activating glycolysis/AKT pathway.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  25. Prognostic factors and outcomes of surgical intervention for patients with spinal metastases secondary to lung cancer: an update systematic review and meta analysis.2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society免费全文
  26. Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy.2023Expert opinion on investigational drugs
  27. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.2023Frontiers in immunology免费全文
  28. Platycodin D induces neutrophil apoptosis by downregulating PD-L1 expression to inhibit breast cancer pulmonary metastasis.2023International immunopharmacology
  29. In stage IV pulmonary adenocarcinoma patients, treatment with Traditional Chinese Medicine alone gives prognostically superior results to treatment with Platinum-Based Chemotherapy alone.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  30. Active post-transcriptional regulation and ACLY-mediated acetyl-CoA synthesis as a pivotal target of Shuang-Huang-Sheng-Bai formula for lung adenocarcinoma treatment.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  31. Camptothecin-Loaded and Manganese Dioxide-Coated Polydopamine Nanomedicine Used for Magnetic Resonance Imaging Diagnosis and Chemo-Photothermal Therapy for Lung Cancer.2022International journal of nanomedicine免费全文
  32. A novel model based on liquid-liquid phase separation-Related genes correlates immune microenvironment profiles and predicts prognosis of lung squamous cell carcinoma.2022Journal of clinical laboratory analysis免费全文
  33. Feiyanning downregulating CXCLs/CXCR2 axis to suppress TANs infiltration in the prevention of lung cancer metastasis.2022Journal of ethnopharmacology
  34. Mechanism underlying the effect of Liujunzi decoction on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy.2022Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan免费全文
  35. Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report.2022Medicine免费全文
  36. To study the mechanism of Scutellariae Radix and Astragaloside in the treatment of lung cancer based on network pharmacology.2022Medicine免费全文
  37. Paclitaxel-loaded and folic acid-modified PLGA nanomedicine with glutathione response for the treatment of lung cancer.2021Acta biochimica et biophysica Sinica
  38. Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  39. Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study of 855 Cases.2021Chinese journal of integrative medicine
  40. Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer.2021Current pharmaceutical biotechnology
  41. Chinese herbal medicine Feiyanning cooperates with cisplatin to enhance cytotoxicity to non-small-cell lung cancer by inhibiting protective autophagy.2021Journal of ethnopharmacology
  42. Jinfukang inhibits lung cancer metastasis by upregulating CX3CL1 to recruit NK cells to kill CTCs.2021Journal of ethnopharmacology
  43. Jinfukang regulates integrin/Src pathway and anoikis mediating circulating lung cancer cells migration.2021Journal of ethnopharmacology
  44. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.2021Medicine免费全文
中文论文(未计入)1
  1. [The TCR repertoire diversity and its application in the prevention and treatment of lung cancer].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Retrospective Study状态不明NCT04397432研究中心2020-08 启动
  2. Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)状态不明NCT03986528研究中心IV期2019-08 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 36 篇,占 0.2%。

牵头论文
36
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 8820222023: 6620232024: 7720242025: 772025

上海有 19 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    分期
    IV期
    开始
    2021-06
    发布
    登记号
    NCT04790305

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 26 家列出的医院为研究中心上海、北京、南京、合肥、宁波、广州、扬州、武汉、沈阳、济南、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文36
  1. Nobiletin and polydatin synergistically alleviate triple-negative breast cancer liver metastasis via suppressing ECM1a-mediated fatty acid biosynthesis.2026Acta pharmacologica Sinica
  2. Transcription factor occupancy limits DNA methylation and determines ICAM1 expression in breast cancer.2025Acta biochimica et biophysica Sinica免费全文
  3. Integrin β1 in breast cancer: mechanisms of progression and therapy.2025Breast cancer (Tokyo, Japan)
  4. Elucidating the Pharmacological Basis of Xianling Cifang Granules Against Breast Cancer. A Metabolomic Profiling Study.2025Drug design, development and therapy免费全文
  5. Multiparametric MRI for differentiating idiopathic granulomatous mastitis from invasive breast cancer:Improving radiologists' diagnostic accuracy.2025European journal of radiology
  6. A pharmacokinetic study of four bone-protective compounds after oral administration of WSZG extract in primary breast cancer mice.2025Journal of pharmaceutical and biomedical analysis
  7. Wenshen Zhuanggu Fang reduces breast cancer bone metastasis by regulating macrophage polarization: a bioinformatics analysis combined with experimental validation.2025Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan免费全文
  8. Impact of serum lipids on prognosis in breast cancer patients: a systematic review and meta-analysis.2025World journal of surgical oncology免费全文
  9. Integrated network pharmacology and experimental verification to explore the potential mechanism of San Ying decoction for treating triple-negative breast cancer.2024Acta biochimica et biophysica Sinica免费全文
  10. Xianling Lianxia formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer.2024Acta biochimica et biophysica Sinica免费全文
  11. Non-pharmaceutical interventions for depressive symptoms in patients with breast cancer: protocol for a systematic review and network meta-analysis.2024BMJ open免费全文
  12. Comprehensive review of drug-mediated ICD inhibition of breast cancer: mechanism, status, and prospects.2024Clinical and experimental medicine免费全文
  13. OSU-T315 overcomes immunosuppression in triple-negative breast cancer by targeting the ILK/NF-κB signaling pathway to enhance immunotherapeutic efficacy.2024International immunopharmacology
  14. Association between red cell distribution width and all-cause mortality in patients with breast cancer: A retrospective analysis using MIMIC-IV 2.0.2024PloS one免费全文
  15. Tumor-derived exosomal ICAM1 promotes bone metastasis of triple-negative breast cancer by inducing CD8+ T cell exhaustion.2024The international journal of biochemistry & cell biology
  16. Non-pharmaceutical interventions in complementary and alternative medicine for insomnia in breast cancer survivors: a protocol for a systematic review and network meta-analysis.2023BMJ open免费全文
  17. Xianlinglianxiafang Inhibited the growth and metastasis of triple-negative breast cancer via activating PPARγ/AMPK signaling pathway.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  18. Benign breast disease with malignant imaging features: a case report.2023Journal of medical case reports免费全文
  19. Molecular mechanism of Ruxian Shuhou prescription in the treatment of triple-negative breast cancer based on network pharmacology.2023Medicine免费全文
  20. Development and validation of novel defined pyroptosis-related gene signature for progression-free survival prediction in patients with breast invasive carcinoma.2023Minerva surgery
  21. Citri Reticulatae Pericarpium-Reynoutria japonica Houtt. herb pair suppresses breast cancer liver metastasis by targeting ECM1-mediated cholesterol biosynthesis pathway.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling.2022Acta pharmacologica Sinica免费全文
  23. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.2022Annals of palliative medicine
  24. ICAM1 promotes bone metastasis via integrin-mediated TGF-β/EMT signaling in triple-negative breast cancer.2022Cancer science免费全文
  25. Primary highly differentiated breast angiosarcoma in an adolescent girl.2022European review for medical and pharmacological sciences
  26. Cancer Risk in Hashimoto's Thyroiditis: a Systematic Review and Meta-Analysis.2022Frontiers in endocrinology免费全文
  27. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.2022Frontiers in immunology免费全文
  28. MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer.2022Investigational new drugs免费全文
  29. Identifying the anti-metastasis effect of Anhydroicaritin on breast cancer: Coupling network pharmacology with experimental validation.2022Journal of ethnopharmacology
  30. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer.2021Aging免费全文
  31. Ruyiping formula inhibits metastasis via the microRNA-134-SLUG axis in breast cancer.2021BMC complementary medicine and therapies免费全文
  32. Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. Polysaccharide-rich extract from Polygonatum sibiricum protects hematopoiesis in bone marrow suppressed by triple negative breast cancer.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  34. Qigong for women with breast cancer: An updated systematic review and meta-analysis.2021Complementary therapies in medicine
  35. Comprehensive Analysis of Prognostic and Immune Infiltrates for RAD51 in Human Breast Cancer.2021Critical reviews in eukaryotic gene expression
  36. The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.2021Oncology research and treatment
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Clinical Study on Auricular Points Sticking Plus Chinese Medication for Hot Flashes in Breast Cancer Women状态不明NCT03540251牵头方不分期2019-01 启动
  2. Efficacy of Acupuncture Treatment for Breast Cancer-associated Insomnia进行中,不再招募NCT05510700牵头方(推断)不分期2022-10 启动
  3. Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer正在招募NCT04790305研究中心IV期2021-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

上海有 14 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025

上海有 45 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

上海有 27 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

上海有 9 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.1%。

牵头论文
5
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 1120232024: 0020242025: 112025

上海有 17 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Chaigui Longmu Ejiao Paste for Ischemic Heart Disease
    分期
    II期
    开始
    2026-03
    发布
    登记号
    NCT07478328

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海中医药大学附属龙华医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊柱侧弯

Scoliosis

2021–2025 年中国大陆作者发表的 925 篇脊柱侧弯 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

上海有 12 家医院列在脊柱侧弯下全国有 107 家医院列在脊柱侧弯下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的脊柱侧弯开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

上海有 26 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

上海有 23 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文1
  1. Clinicopathological Characteristics and Outcomes of Immunoglobulin A Nephropathy with Different Types of Dyslipidemia: A Retrospective Single-Center Study.2023Kidney & blood pressure research免费全文
早期论文(2016–2020 年)1
  1. Personalized evaluation based on quantitative proteomics for drug-treated patients with chronic kidney disease.2016Journal of molecular cell biologyRCT
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Integrative Medicine of IgA Nephropathy状态不明NCT02712697牵头方(推断)不分期2016-06 启动
  2. Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath状态不明NCT01879514牵头方(推断)不分期2010-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

上海有 16 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 13 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

上海有 9 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

上海中医药大学附属龙华医院

Longhua Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Longhua Hospital Shanghai University of Traditional Chinese Medicine; Shanghai Longhua Hospital; LongHua Hospital

提出更正下载数据